Increasing Costs and Limited Mortality Improvement in Incident Metastatic Lung Cancer in German Statutory Health Insurance Claims, 2011–2024

+87.5% costs, limited survival gains: new ISPOR 2026 poster on metastatic lung cancer in Germany

The GIPAM team analysed anonymized German statutory health insurance claims data from 2011 to 2024 to track 12-month overall survival and inflation-adjusted healthcare costs in 14 annual cohorts of patients with incident metastatic lung cancer (mLC).

Standardized 12-month survival improved only modestly and inconsistently (61.6% in 2011 vs. 68.4% in 2024), while costs per patient rose from €31,591 to €59,236. The outpatient drug share of costs increased from 26% to 43%, while the inpatient share declined from 65% to 50%.

Learn more about the poster below.